Although only a few clinical trials supported that TYK2 inhibitors appeared to improve disease activity among patients with ulcerative colitis, alopecia areata, atopic dermatitis, or active non-segmental vitiligo, these findings need to be confirmed in larger studies, especially for ulcerative colitis, for which there was conflicting evidence in previous trials. Here, TYK2 is linked to ulcerative colitis.